GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption.

Aún no traducido Aún no traducido
Autores
Categoría Estudio primario
RevistaDermatology and therapy
Año 2012
INTRODUCTION: Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin's lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established. CASE REPORT: The authors report a case of a 62-year-old patient who developed widespread lichenoid eruption as a result of GA101 treatment for his follicular non-Hodgkin's lymphoma. CONCLUSION: This is the first case report of cutaneous side effects of GA101.
Epistemonikos ID: 5d30fa69e25417c68d795f84d5717c9057af26f2
First added on: Jul 06, 2022